RGC Valuation

Regencell Bioscience Holdings Ltd

Add to Watchlist

Advanced Chart

15.050

-0.13(-0.856%)1D

Overview
Forecast
Valuation
Earnings

RGC Relative Valuation

RGC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RGC is overvalued; if below, it's undervalued.

Historical Valuation

Regencell Bioscience Holdings Ltd (RGC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Regencell Bioscience Holdings Ltd (RGC) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：14.94

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1117.82

P/B

Median3y

118.68

Median5y

84.66

0.00

FCF Yield

Median3y

-1.41

Median5y

-1.03

Competitors Valuation Multiple

The average P/S ratio for RGC's competitors is 4.32, providing a benchmark for relative valuation. Regencell Bioscience Holdings Ltd Corp (RGC) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

RGC.O

Regencell Bioscience Holdings Ltd

Loss

Average P/S: 4.32

7.44B